We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
ACTB
SECTIONS
  • TISSUE
  • BRAIN
  • SINGLE CELL TYPE
  • TISSUE CELL TYPE
  • PATHOLOGY
  • DISEASE
  • IMMUNE CELL
  • BLOOD PROTEIN
  • SUBCELLULAR
  • CELL LINE
  • STRUCTURE
  • INTERACTION
ABOUT
  • INTRODUCTION
  • HISTORY
  • ORGANIZATION
  • PUBLICATIONS
  • ANTIBODY SUBMISSION
  • ANTIBODY AVAILABILITY
  • ACKNOWLEDGMENTS
  • CONTACT
NEWS
  • NEWS ARTICLES
  • PRESS ROOM
LEARN
  • DICTIONARY
  • PROTEIN CLASSES
  • PROTEIN EVIDENCE
  • METHODS
  • EDUCATIONAL VIDEOS
DATA
  • DOWNLOADABLE DATA
  • PUBLICATION DATA
  • RELEASE HISTORY
  • SARS-COV-2
HELP
  • ANTIBODY VALIDATION
  • ASSAYS & ANNOTATION
  • DISCLAIMER
  • HELP & FAQ
  • PRIVACY STATEMENT
  • LICENCE & CITATION
Fields »
Search result

Field
Term
Gene name
Class
Subclass
Class
Keyword
Chromosome
External id
Tissue
Cell type
Expression
Patient ID
Tissue
Category
Cluster
Reliability
Brain region
Category
Brain region
Category
Brain region
Category
Cluster
Reliability
Cell type
Category
Cluster
Tissue
Cell type
Enrichment
Cancer
Prognosis
Cancer
Category
Cell type
Category
Cell lineage
Category
Cluster
Annotation
Disease
Location
Searches
Location
Cell line
Type
Phase
Reliability
Cancer type
Category
Cluster
Interacting gene
Number of interactions
Pathway
Category
Score
Score
Score
Validation
Validation
Validation
Validation
Antibodies
Protein structure
In atlas
Column


  • SUMMARY

  • TISSUE

  • BRAIN

  • SINGLE CELL

  • TISSUE CELL

  • PATHOLOGY

  • DISEASE

  • IMMUNE

  • BLOOD

  • SUBCELL

  • CELL LINE

  • STRUCTURE

  • INTERACTION

  • ACTB
PATHOLOGY TESTIS CANCER Show tissue menu
BREAST CANCER CARCINOID CERVICAL CANCER COLORECTAL CANCER ENDOMETRIAL CANCER GLIOMA HEAD AND NECK CANCER LIVER CANCER LUNG CANCER LYMPHOMA
MELANOMA OVARIAN CANCER PANCREATIC CANCER PROSTATE CANCER RENAL CANCER SKIN CANCER STOMACH CANCER TESTIS CANCER THYROID CANCER UROTHELIAL CANCER
ANTIBODIES
AND
VALIDATION
Dictionary
Testis cancer
Human pathology
Testis cancer
TESTIS CANCER - Interactive survival scatter ploti

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.

ACTB is not prognostic in testis cancer


Stage:


Survival analysis
Current cut offi

Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.

:
Best expression cut offi

Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .

When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.

: 1808.93
Median expressioni

Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.

: N/A
Median follow up timei

Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.

: N/A
P scorei

Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.

N/A
5-year survival highi

5-year survival for patients with higher expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

N/A
5-year survival lowi

5-year survival for patients with lower expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

N/A
TCGA RNA samplesi

RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .

Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.

Average FPKM 1806.2
Number of samples 134
Samples
Sample Description FPKM
TCGA-2G-AAGV-01A 23 years, male, white, alive, 4527 days 3319.4
TCGA-ZM-AA0N-01A 44 years, male, white, stage:ib, alive, 634 days 3198.9
TCGA-VF-A8AE-01A 39 years, male, white, stage:ia, alive, 727 days 2918.5
TCGA-ZM-AA0D-01A 34 years, male, white, stage:ia, alive, 848 days 2808.7
TCGA-2G-AALP-01A 43 years, male, white, stage:iiib, alive, 2645 days 2780.3
TCGA-YU-A90S-01A 26 years, male, white, stage:ia, alive, 971 days 2745.2
TCGA-VF-A8A9-01A 31 years, male, white, stage:ia, alive, 1119 days 2656.4
TCGA-4K-AA1H-01A 26 years, male, white, stage:ia, alive, 518 days 2623.1
TCGA-2G-AAGT-01A 30 years, male, white, stage:is, alive, 4406 days 2574.3
TCGA-2G-AAFM-01A 31 years, male, white, stage:iia, alive, 503 days 2570.7
TCGA-2G-AAKG-01A 22 years, male, white, stage:i, alive, 6598 days 2538.2
TCGA-XE-AAOB-01A 27 years, male, white, stage:is, dead, 513 days 2515.7
TCGA-2G-AAFY-01A 24 years, male, white, stage:iia, alive, 1099 days 2505.3
TCGA-2G-AAL7-01A 32 years, male, white, stage:is, alive, 3991 days 2492.7
TCGA-2G-AAFN-01A 26 years, male, white, stage:iiib, alive, 773 days 2448.2
TCGA-XE-AAOJ-01A 24 years, male, white, stage:is, alive, 1550 days 2432.9
TCGA-4K-AA1I-01A 26 years, male, white, stage:ia, alive, 3 days 2430.7
TCGA-2G-AAG7-01A 33 years, male, white, stage:is, alive, 2475 days 2373.6
TCGA-YU-AA4L-01A 27 years, male, black or african american, stage:iiic, alive, 1573 days 2355.4
TCGA-2G-AAHN-01A 32 years, male, white, stage:i, alive, 6445 days 2349.1
TCGA-2G-AAG8-01A 21 years, male, white, stage:ib, alive, 2289 days 2340.3
TCGA-2G-AAG0-01A 23 years, male, white, stage:is, alive, 1529 days 2339.9
TCGA-ZM-AA0B-01A 32 years, male, white, stage:ia, alive, 838 days 2317.4
TCGA-VF-A8A8-01A 18 years, male, white, stage:ia, alive, 1131 days 2312.7
TCGA-ZM-AA0F-01A 35 years, male, white, stage:ia, alive, 681 days 2294.2
TCGA-2G-AAHL-01A 26 years, male, white, stage:i, alive, 7081 days 2270.9
TCGA-2G-AAGN-01A 41 years, male, white, stage:iiib, alive, 3656 days 2263.7
TCGA-2G-AAGK-01A 20 years, male, white, stage:is, alive, 3621 days 2262.4
TCGA-VF-A8AD-01A 36 years, male, white, stage:ib, alive, 1006 days 2248.5
TCGA-XY-A8S2-01A 67 years, male, white, stage:i, alive, 672 days 2241.9
TCGA-VF-A8AB-01A 31 years, male, black or african american, stage:ia, alive, 760 days 2217.8
TCGA-2G-AAGF-01A 28 years, male, white, stage:is, alive, 2734 days 2169.8
TCGA-XY-A8S3-01B 24 years, male, white, stage:is, alive, 843 days 2140.5
TCGA-X3-A8G4-01A 33 years, male, white, stage:is, alive, 856 days 2140.1
TCGA-2G-AAGZ-01A 27 years, male, white, stage:iiia, alive, 5233 days 2135.3
TCGA-ZM-AA0H-01A 50 years, male, white, stage:is, alive, 1736 days 2124.1
TCGA-ZM-AA0E-01A 39 years, male, white, stage:ia, alive, 811 days 2121.4
TCGA-2G-AAGP-01A 33 years, male, white, stage:iia, alive, 4018 days 2116.9
TCGA-W4-A7U4-01A 23 years, male, white, alive, 738 days 2109.6
TCGA-2G-AAGS-01A 39 years, male, white, stage:iiib, alive, 4816 days 2074.9
TCGA-2G-AAFG-01A 30 years, male, white, stage:is, alive, 6183 days 2073.6
TCGA-XE-AAOF-01A 50 years, male, asian, stage:ia, alive, 1268 days 2046.5
TCGA-ZM-AA05-01A 36 years, male, white, stage:iic, alive, 1126 days 2034.2
TCGA-2G-AAFO-01A 33 years, male, white, stage:iia, alive, 685 days 2031.1
TCGA-2G-AAHA-01A 48 years, male, white, stage:ib, alive, 3349 days 2008.2
TCGA-VF-A8AC-01A 29 years, male, white, stage:ia, alive, 1083 days 2000.9
TCGA-2G-AAKL-01A 26 years, male, white, stage:ii, alive, 7023 days 1982.0
TCGA-WZ-A8D5-01A 38 years, male, white, alive, 774 days 1965.1
TCGA-2G-AAKD-01A 18 years, male, white, stage:iii, alive, 6340 days 1954.1
TCGA-2G-AAHC-01A 33 years, male, white, stage:is, alive, 5539 days 1905.2
TCGA-2G-AAGW-01A 38 years, male, white, stage:is, alive, 4899 days 1893.7
TCGA-SN-A84Y-01A 18 years, male, white, stage:is, alive, 524 days 1887.4
TCGA-2G-AAG6-01A 24 years, male, white, stage:is, alive, 2231 days 1862.8
TCGA-2G-AAFL-01A 35 years, male, white, stage:ib, alive, 750 days 1860.3
TCGA-2G-AAKH-01A 19 years, male, white, stage:ii, alive, 6862 days 1854.0
TCGA-YU-AA61-01A 29 years, male, white, stage:is, alive, 864 days 1852.8
TCGA-2G-AAFV-01A 31 years, male, white, stage:is, alive, 1389 days 1847.8
TCGA-YU-A90P-01A 25 years, male, white, stage:ia, alive, 2069 days 1841.1
TCGA-2G-AAH4-01A 34 years, male, white, stage:ii, alive, 6210 days 1839.4
TCGA-2G-AAGC-01A 28 years, male, white, stage:is, alive, 2585 days 1830.3
TCGA-YU-A90Y-01A 23 years, male, black or african american, stage:iiic, dead, 17 days 1787.6
TCGA-2G-AAGA-01A 38 years, male, white, stage:iia, alive, 2439 days 1757.8
TCGA-XE-AAO6-01A 47 years, male, white, stage:ia, alive, 240 days 1750.3
TCGA-XE-A8H1-01A 24 years, male, white, stage:is, alive, 209 days 1740.6
TCGA-2G-AAEX-01A 38 years, male, white, stage:is, alive, 1259 days 1736.8
TCGA-XE-A9SE-01A 35 years, male, white, stage:ia, alive, 708 days 1729.8
TCGA-W4-A7U3-01A 26 years, male, white, alive, 149 days 1725.1
TCGA-2G-AAGJ-01A 28 years, male, black or african american, stage:ia, alive, 2938 days 1708.6
TCGA-2G-AAGX-01A 22 years, male, white, stage:ia, alive, 5514 days 1701.0
TCGA-2G-AAKM-01A 14 years, male, white, stage:ii, dead, 6972 days 1694.0
TCGA-2G-AAGE-01A 21 years, male, white, stage:is, alive, 2478 days 1687.2
TCGA-2G-AAFH-01A 38 years, male, white, stage:iib, alive, 1375 days 1680.8
TCGA-2G-AAGI-01A 33 years, male, white, stage:is, alive, 3137 days 1680.1
TCGA-XE-A8H5-01A 29 years, male, stage:is, alive, 1217 days 1670.3
TCGA-2G-AAGY-01A 28 years, male, white, stage:is, alive, 5329 days 1662.0
TCGA-2G-AAFI-01A 41 years, male, white, stage:ib, alive, 675 days 1644.8
TCGA-XE-AAOD-01A 39 years, male, white, stage:ib, alive, 2058 days 1623.3
TCGA-2G-AAFE-01A 37 years, male, white, stage:iia, alive, 4702 days 1621.7
TCGA-2G-AAFZ-01A 32 years, male, white, stage:iii, alive, 1353 days 1618.0
TCGA-2G-AAL5-01A 31 years, male, white, stage:i, alive, 7437 days 1616.2
TCGA-XY-A9T9-01A 37 years, male, white, stage:is, alive, 281 days 1604.8
TCGA-2G-AAGG-01A 20 years, male, white, stage:iiic, alive, 2611 days 1604.5
TCGA-2G-AAH2-01A 20 years, male, white, stage:is, alive, 6060 days 1603.9
TCGA-XE-A8H4-01A 23 years, male, white, stage:ia, alive, 559 days 1602.3
TCGA-XE-AANI-01A 37 years, male, white, stage:is, alive, 1041 days 1595.7
TCGA-VF-A8AA-01A 51 years, male, white, stage:i, alive, 1146 days 1594.7
TCGA-SN-A84X-01A 21 years, male, white, stage:is, alive, 312 days 1578.7
TCGA-YU-A912-01A 34 years, male, black or african american, stage:iiic, alive, 866 days 1563.8
TCGA-YU-A90W-01A 45 years, male, white, stage:ia, alive, 1113 days 1550.8
TCGA-2G-AAG9-01A 25 years, male, white, stage:iiib, alive, 2234 days 1547.5
TCGA-WZ-A7V4-01A 28 years, male, white, stage:i, alive, 894 days 1547.0
TCGA-SB-A6J6-01A 22 years, male, white, stage:ia, alive, 413 days 1542.2
TCGA-4K-AAAL-01A 31 years, male, white, stage:is, alive, 483 days 1540.4
TCGA-2G-AAG5-01A 36 years, male, white, stage:is, alive, 2299 days 1539.6
TCGA-XE-AAO4-01A 40 years, male, white, stage:ia, alive, 367 days 1536.6
TCGA-2G-AAH0-01A 30 years, male, white, stage:is, alive, 5477 days 1527.5
TCGA-XE-AAO3-01A 33 years, male, asian, stage:i, alive, 2857 days 1521.9
TCGA-XE-AAOL-01A 38 years, male, black or african american, stage:i, alive, 13 days 1518.0
TCGA-2G-AAF4-01A 30 years, male, white, stage:i, alive, 2315 days 1482.6
TCGA-2G-AAHT-01A 32 years, male, white, stage:is, alive, 542 days 1467.5
TCGA-YU-A94I-01A 66 years, male, stage:ia, alive, 536 days 1466.9
TCGA-XY-A89B-01A 35 years, male, white, stage:ia, alive, 471 days 1431.7
TCGA-SB-A76C-01A 38 years, male, white, alive, 42 days 1424.3
TCGA-2G-AAH8-01A 45 years, male, white, stage:iiic, alive, 2248 days 1415.9
TCGA-2G-AAEW-01A 31 years, male, white, stage:is, dead, 618 days 1396.3
TCGA-SN-A6IS-01A 26 years, male, white, stage:is, alive, 496 days 1393.2
TCGA-XE-AANR-01A 24 years, male, white, stage:i, alive, 14 days 1371.6
TCGA-2G-AAF1-01A 28 years, male, asian, stage:is, alive, 1403 days 1354.9
TCGA-2G-AAHP-01A 31 years, male, white, stage:is, alive, 5667 days 1350.3
TCGA-WZ-A7V3-01A 20 years, male, white, stage:i, alive, 753 days 1349.8
TCGA-2G-AAF6-01A 28 years, male, white, stage:is, alive, 3491 days 1337.8
TCGA-2G-AAGM-01A 51 years, male, white, stage:is, alive, 3891 days 1320.3
TCGA-2G-AAGO-01A 41 years, male, white, stage:is, alive, 4026 days 1312.6
TCGA-XE-AAOC-01A 31 years, male, white, stage:ia, alive, 270 days 1304.5
TCGA-2G-AAG3-01A 53 years, male, white, stage:is, alive, 1593 days 1282.6
TCGA-2G-AAFJ-01A 23 years, male, asian, alive, 792 days 1260.8
TCGA-2X-A9D5-01A 49 years, male, white, stage:i, alive, 435 days 1251.8
TCGA-S6-A8JW-01A 37 years, male, white, stage:is, alive, 698 days 1249.8
TCGA-YU-A94D-01A 28 years, male, stage:iiib, alive, 2167 days 1249.4
TCGA-XE-AANJ-01A 39 years, male, white, stage:is, alive, 2007 days 1238.9
TCGA-XE-AANV-01A 52 years, male, stage:ib, alive, 1701 days 1233.6
TCGA-SN-A84W-01A 30 years, male, white, stage:is, alive, 293 days 1223.7
TCGA-WZ-A7V5-01A 27 years, male, white, stage:i, alive, 1061 days 1217.1
TCGA-W4-A7U2-01A 26 years, male, white, alive, 1263 days 1209.6
TCGA-2X-A9D6-01A 42 years, male, white, stage:i, alive, 607 days 1170.8
TCGA-2G-AAHG-01A 25 years, male, white, stage:i, alive, 1819 days 1158.8
TCGA-4K-AA1G-01A 34 years, male, white, stage:is, alive, 436 days 1121.1
TCGA-S6-A8JY-01A 27 years, male, white, stage:is, alive, 278 days 1105.0
TCGA-ZM-AA06-01A 45 years, male, white, stage:ib, alive, 1498 days 1094.2
TCGA-2G-AAF8-01A 33 years, male, white, stage:ia, alive, 3911 days 1046.1
TCGA-S6-A8JX-01A 27 years, male, white, stage:ib, alive, 552 days 982.1
TCGA-2G-AAH3-01A 20 years, male, white, stage:i, alive, 1822 days 897.1
TCGA-SO-A8JP-01A 29 years, male, white, stage:i, alive, 540 days 747.7
TCGA-YU-A90Q-01A 21 years, male, stage:ib, alive, 1964 days 711.0
Show allShow less
TESTIS CANCER - Protein expressioni

A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.

Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

 

Antibody stainingi

Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells.

Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample.


Antibody HPA041264

Antibody HPA041271

Antibody CAB002621
 Staining
  High
  Medium
  Low
  Not detected
 Intensity
  Strong
  Moderate
  Weak
  Negative
 Quantity
  >75%
  75%-25%
  <25%
  None
 Location
  Nuclear
  Cytoplasmic/membranous
  Cytoplasmic/membranous,nuclear
  None
Click images for details

Contact

  • NEWS ARTICLES
  • PRESS ROOM

The Project

  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS

The Human Protein Atlas

  • DOWNLOADABLE DATA
  • LICENCE & CITATION
  • HELP & FAQ
The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg Foundation.


contact@proteinatlas.org